<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128488</url>
  </required_header>
  <id_info>
    <org_study_id>2019P001962</org_study_id>
    <secondary_id>1K23HL147799-01</secondary_id>
    <nct_id>NCT04128488</nct_id>
  </id_info>
  <brief_title>Effects of Gender-Affirming Hormone Therapy Among Transgender Women</brief_title>
  <official_title>Effects of Gender-Affirming Hormone Therapy Among Transgender Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, investigators plan to evaluate the cardiometabolic effects of initiating
      gender-affirming hormone therapy among transgender women with HIV. As part of this study,
      participants will undergo cardiovascular and metabolic phenotyping before and after 12 months
      of gender-affirming hormone therapy. Cardiovascular phenotyping will include cardiac MRI/MRS
      imaging to evaluate cardiac function and structure. Metabolic phenotyping will include oral
      glucose tolerance testing, abdominal MR imaging to evaluate visceral adiposity, and whole
      body, lumbar, and hip DEXA imaging to evaluate fat and lean body mass as well as bone mineral
      density, respectively. Traditional markers of CVD risk as well as immune, hormonal, and
      coagulation parameters will also be assessed longitudinally.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visceral Adipose Tissue</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Intramyocardial Triglyceride Content on Cardiac MRS</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Function on Cardiac MRI</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Myocardial Fibrosis on Cardiac MRI</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glucose and Insulin Parameters on Oral Glucose Tolerance Testing</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Density</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hormonal Parameters</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coagulation Parameters</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Transgender Women</condition>
  <condition>HIV/AIDS</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Metabolic Disease</condition>
  <condition>Coagulopathy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Abdominal MR Imaging</intervention_name>
    <description>Imaging to visceral adipose tissue</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac MRI/MRS</intervention_name>
    <description>Imaging to evaluate cardiac function and structure</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Glucose Tolerance Testing</intervention_name>
    <description>Blood testing to evaluate changes in glucose and insulin in response to oral glucose load</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole Body, Lumbar Spine, and Hip DEXA Imaging</intervention_name>
    <description>Imaging to evaluate fat and lean body mass as well as bone mineral density</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Transgender Women with HIV
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  transgender women

          -  HIV positive

          -  age ≥18

          -  on ART therapy for ≥3 months

          -  initiation of testosterone suppression with spironolactone and estrogen therapy with
             oral 17-β estradiol by medical provider

        Exclusion Criteria:

          -  CD4 count&lt;50

          -  history of CAD, ACS, ASCVD risk score ≥ 7.5%, LDL-C ≥ 190, or angina (e.g. current
             indication for statin use)

          -  history of heart failure

          -  history of diabetes

          -  eGFR &lt; 30 ml/min/1.73m2

          -  standard contraindication to MRI, including history of severe allergy to gadolinium or
             Dotarem

          -  prior orchiectomy

          -  current or past gender-affirming hormone therapy within the last 12 months

          -  current or past anti-platelet therapy or anti-coagulant therapy within the last 6
             months •current or past statin therapy within the last 6 months

          -  concurrent enrollment in conflicting research study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Transgender Women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mabel Toribio</last_name>
    <phone>617-724-2826</phone>
    <email>mptoribio@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mabel Toribio</last_name>
      <phone>617-724-2826</phone>
      <email>mptoribio@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Mabel Toribio</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

